ABUS - Arbutus Biopharma Corporation
4.44 0.00 (0.00%)
After hours: 4:52PM EDT
| Previous Close | 4.71 |
| Open | 4.65 |
| Bid | 4.21 x 3100 |
| Ask | 4.49 x 2900 |
| Day's Range | 4.23 - 4.65 |
| 52 Week Range | 4.01 - 12.60 |
| Volume | 567,667 |
| Avg. Volume | 492,109 |
| Market Cap | 245.995M |
| Beta (3Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.23 |
| Earnings Date | May 2, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.32 |
- Simply Wall St.•yesterday
What Kind Of Risk Should You Expect For Arbutus Biopharma Corporation (NASDAQ:ABUS)?
If you’re interested in Arbutus Biopharma Corporation (NASDAQ:ABUS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
- Zacks•8 days ago
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
- ACCESSWIRE•8 days ago
Today's Research Reports on Trending Tickers: Arbutus Biopharma and Akcea Therapeutics
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / U.S. equities finished mostly lower on Tuesday as interest rate increases and rising bond yields continued to put pressure on stocks. The Dow Jones Industrial ...
Market Realist•9 days agoWhy Arbutus Biopharma Stock Plunged 24.4% Today
Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09. Arbutus Biopharma’s closing price on October 8 represents ~111.0% growth from its 52-week low of $4.30 on December 15, 2017. On August 2, Arbutus Pharma hit its 52-week high of $12.60.
- Motley Fool•9 days ago
Here's Why Arbutus Biopharma Corp. Is Tanking Today
The clinical-stage biotech reported good news and bad news -- with the bad outweighing the good.
- GlobeNewswire•9 days ago
Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
AB-506, the Company’s second generation capsid inhibitor, has progressed through the healthy volunteer portion of a multi-component phase 1a/1b study in which it was demonstrated to be generally safe and well-tolerated after 10 days of dosing. This month, AB-506 will enter the 28-day HBV patient portion of the trial, where it will be evaluated both with and without a nucleoside analog.
- GlobeNewswire•16 days ago
Arbutus to Present at Chardan’s Genetic Medicines Conference
WARMINSTER, Pa., Oct. 02, 2018 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Zacks•24 days ago
Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock?
Investors need to pay close attention to Arbutus (ABUS) stock based on the movements in the options market lately.
Market Realist•last monthWhy Dicerna Pharmaceuticals Stock Rose 7.7% Yesterday
On September 13, Dicerna Pharmaceuticals (DRNA) stock rose 7.71% to $16.62 from its previous day’s close of $15.43. In the trial, Dicerna’s lead drug candidate, DCR-PHXC, showed that it was capable of bringing urinary oxalate levels to a normal or near-normal range in individuals with primary hyperoxaluria type 1 and hyperoxaluria type 2. The company is conducting studies with DCR-PHXC and investigating its potential as a therapy for all forms of hyperoxaluria.
Market Realist•last monthWhy Arrowhead Pharmaceuticals Stock Is Skyrocketing Today
Today, Arrowhead Pharmaceuticals (ARWR) stock is trading at $20.12, which represents ~42.7% growth from yesterday’s close of $14.10. Arrowhead Pharmaceuticals also hit its 52-week high of $22.39 today.
- GlobeNewswire•2 months ago
Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference
WARMINSTER, Pa., Aug. 28, 2018-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, ...
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for GSV Capital, NantHealth, Gold Fields, Sogou Inc. Sponsored ADR, Clementia Pharmaceuticals, and Arbutus Biopharma — Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of GSV ...
- GlobeNewswire•2 months ago
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company's lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals, Inc. (ALNY), announced that their new drug application (NDA) for ONPATTRO, an RNAi therapeutic, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of hereditary ATTR amyloidosis with polyneuropathy. Because ONPATTRO is enabled by our proprietary LNP technology, this approval triggers a royalty to Arbutus and provides us with important non-dilutive revenue to support our HBV cure mission, through several important clinical milestones next year,” said Dr. Mark Murray, Arbutus’ President and CEO.
- GlobeNewswire•2 months ago
Arbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference
WARMINSTER, Pa., Aug. 09, 2018-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, ...
- GlobeNewswire•3 months ago
Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update
-Phase 1 a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated. -Phase 1 a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expected to begin in the second half of ...
- ACCESSWIRE•3 months ago
Arbutus Biopharma Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Arbutus Biopharma Corporation (NASDAQ: ABUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...
Market Realist•3 months agoContraVir Stock Rose on Clinical Trial Progress Report
On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.
- Zacks•3 months ago
Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation (ABUS)
- Motley Fool•3 months ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these hot biotech stocks get even hotter?
- Motley Fool•3 months ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these hot biotech stocks keep the momentum going?
- Benzinga•3 months ago
Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run
Arbutus Biopharma Corp (NASDAQ: ABUS ) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally. The Analyst B. Riley FBR's ...
